Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Pharmacogenomic technologies: a necessary “luxury” for better global public health? | Olivier and Williams-Jones Globalization and Health 2011 7 30 http content 7 1 30 H2 globalization 7 AND HEALTH DEBATE Open Access Pharmacogenomic technologies a necessary luxury for better global public health Catherine Olivier and Bryn Williams-Jones Abstract Background Pharmacogenomic technologies aim to redirect drug development to increase safety and efficacy of individual care. There is much hope that their implementation in the drug development process will help respond to population health needs particularly in developing countries. However there is also fear that novel pharmacogenomic drugs will remain too costly be designed for the needs of the wealthy nations and so constitute an unnecessary luxury for most populations. In this paper we analyse the promise that pharmacogenomic technologies hold for improving global public health and identify strategies and challenges associated with their implementation. Discussion This paper evaluates the capacity of pharmacogenomic technologies to meet six criteria described by the University of Toronto Joint Centre for Bioethics group 1 impact of the technology 2 technology appropriateness 3 capacity to address local burdens 4 feasibility to be implemented in reasonable time 5 capacity to reduce the knowledge gap and 6 capacity for indirect benefits. We argue that the implementation of pharmacogenomic technologies in the drug development process can positively impact population health. However this positive impact depends on how and for which purposes the technologies are used. We discuss the potential of these technologies to stimulate drug discovery in the case of rare orphan diseases or neglected diseases but also to reduce acute adverse drug reactions in infectious disease treatment and prevention which promises to improve global public health. Conclusions The implementation of pharmacogenomic technologies may lead to the development of drugs that appear to be a luxury for .
